🔴 AQST is trading 5.1% down today as FDA setbacks and fraud lawsuits weigh on sentiment

AQST is trading at $4.17 (5.1% down) as investors remain cautious following regulatory and legal challenges surrounding its oral allergy drug, Anaphylm.

• Sentiment is pressured by an FDA deficiency letter regarding the Anaphylm New Drug Application (NDA), creating uncertainty around its approval timeline.
• The company faces multiple securities-fraud class action lawsuits tied to a significant stock price drop in January 2026.
• The downward trend persists despite a broader market rally, highlighting specific concerns over the company's recent setbacks.